InvestorsHub Logo

kevindenver

05/25/21 9:31 PM

#311428 RE: TTTav66 #311424

What an outstanding and appropriate time and venue to release Rett data and guess what it's still in Q2.

Exactly as corporate guidance has been saying all along.

kevindenver

05/25/21 9:35 PM

#311430 RE: TTTav66 #311424

The antiepileptic possibilities of 2-73 has me intrigued too.

Dr. Walter E. Kaufmann will speak at AEDD TRIALS XVI on 6/18, delivering a 10 minutes presentation; Update on Adult and Pediatric Clinical Rett Syndrome ANAVEX2-73 Program. https://aedtrials.com/



As always, thank you for providing your DD findings.

MayoMobile

05/25/21 9:37 PM

#311431 RE: TTTav66 #311424

Hmm, that definitely makes sense considering the “by the end of Q2” deadline.
I wonder if we see PDD before that.

McMagyar

05/26/21 7:27 AM

#311456 RE: TTTav66 #311424

Great find

plexrec

05/26/21 8:12 AM

#311465 RE: TTTav66 #311424

Great find TTT-"Dr. Walter E. Kaufmann will speak "-also prominent at this meeting will be one of our SAB members Dr.Jacquline French--epilepsy specialist--my oh my-does Anavex specialize in this area???? Of course !!!